Leading the way to safer medication
 Crosscheck  Recommender

ATC Group: L04AA36 Ocrelizumab

Anatomical Therapeutic Chemical Classification System

Hierarchical Position

Level
Code
Title
1
L
Antineoplastic and immunomodulating agents
2
L04
Immunosuppressants
3
L04A
Immunosuppressants
4
L04AA
Selective immunosuppressants
5
L04AA36
Ocrelizumab

Active Ingredients

Chemical substance
Description
Ocrelizumab

Ocrelizumab is a recombinant humanised monoclonal antibody that selectively targets CD20-expressing B cells. The precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects in MS is presumed to involve immunomodulation through the reduction in the number and function of CD20-expressing B cells. Following cell surface binding, ocrelizumab selectively depletes CD20-expressing B cells through antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. The capacity of B-cell reconstitution and preexisting humoral immunity are preserved.

Monographs

Monograph
Type
Country
OCREVUS Concentrate for solution for infusion
MPI, EU: SmPC